Page 28 - RxExam's Naplex Theory Review Part-1

www.pharmacyexam.com Krisman

Dose Special Notes

Amlodipine 4). Amlodipine in combination with other drugs:
(Tablet)
(Tablet, ODT) a). Amlodipine and Olmesartan (Azor)
b). Amlodipine and Atorvastatin (Caduet)
c). Amlodipine and Valsartan (Exforge)
d). Amlodipine, Aliskiren and Hydrochlorothiazide (Amturnide)

Isradipine 2.5-10 mg PO 1). Isradipine (DynaCirc) is indicated for the treatment of hypertension.
(Tablet, ER) B.I.D.
(Capsule) 2). The bioavailability of Isradipine (DynaCirc) (increased AUC) is
5-20 mg PO QD increased in elderly patients (above 65 years of age), patients with
(ER). hepatic functional impairment, and patients with mild renal impairment.
Ordinarily, the starting dose should still be 2.5 mg b.i.d. in these patients.

3). DynaCirc CR is a registered trademark for Isradipine GITS -
Gastrointestinal Therapeutic System. It is delivered from the DynaCirc
CR controlled release tablet as follows:
A semipermeable membrane surrounds an osmotically active drug
core. The core is composed of two layers: an "active layer” containing
the drug, and a pharmacologically inert but osmotically active "push"
layer. After ingestion, the tablet over coating is quickly dissipated in the
tract, allowing water to enter the tablet through the semipermeable
membrane.
The polyethylene oxide polymer swells in the osmotic ("push")
layer and exerts pressure against the "active” drug layer, releasing
Isradipine as a fine suspension through the laser-drilled tablet orifice
which has been positioned on the "active" drug layer side.
Drug delivery is essentially constant as long as the osmotic gradient
remains constant and, after either 5 mg or 10 mg of isradipine is released,
gradually falls to a negligible amount. The controlled rate of drug delivery
into the gastrointestinal lumen is independent of pH or gastrointestinal
motility.

Nisoldipine 20-60 mg PO QD 1). Nisoldipine (Sular) is indicated for the treatment of hypertension.
(Tablet, ER) (ER).
2). Nisoldipine extended release tablet consists of an external coat and
an internal core. Both coat and core contain Nisoldipine, the coat as a
slow release formulation and the core as a fast release formulation.

3). Administration with a high fat meal can lead to excessive peak drug
concentration and should be avoided. Grapefruit products should be
avoided before and after dosing.

27